Achieve Life Sciences, Inc. reported a net loss of $10.2 million for the first quarter of 2026, a decrease from the $12.8 million loss recorded in the same period of 2025. The company's total operating expenses for the quarter were $10.5 million, down from $12.9 million year-over-year, primarily due to reduced research and development costs associated with the completion of the ORCA-OL trial. As of March 31, 2026, Achieve had cash, cash equivalents, and marketable securities totaling $29.3 million, compared to $36.4 million at the end of 2025. The company also reported an accumulated deficit of $270.4 million.
In terms of strategic developments, Achieve Life Sciences is focused on the commercialization of its product candidate, cytisinicline, which is aimed at treating nicotine dependence. The company has submitted a New Drug Application (NDA) to the FDA for cytisinicline, which has been accepted for review with a target action date set for June 20, 2026. Achieve has partnered with Adare Pharma Solutions for the manufacturing of cytisinicline, which is expected to enhance supply chain capabilities and reduce costs. However, the company is currently facing a dispute with Sopharma AD regarding the supply agreement for cytisinicline, which could impact commercialization efforts.
Operationally, Achieve Life Sciences has made significant progress in its clinical trials, with the ORCA-OL trial completed in September 2025. The company is also preparing for the potential commercial launch of cytisinicline, with plans to utilize a marketing technology infrastructure and artificial intelligence tools to enhance targeting and performance metrics. The company’s workforce has expanded, reflecting its preparations for commercialization, although specific employee headcount figures were not disclosed.
Looking ahead, Achieve Life Sciences anticipates that the successful commercialization of cytisinicline will depend on obtaining adequate reimbursement and market acceptance from healthcare providers and patients. The company is aware of the competitive landscape, with several other companies developing smoking cessation products, and recognizes the importance of establishing effective distribution and marketing capabilities. Achieve's future financial performance will largely depend on the successful execution of its commercialization strategy and the ability to secure additional funding to support ongoing operations and development activities.
About ACHIEVE LIFE SCIENCES, INC.
Achieve Life Sciences, Inc. is a late-stage clinical specialty pharmaceutical company dedicated to combating nicotine dependence through its product candidate, cytisinicline. Targeting the 29 million U.S. smokers and 11 million e-cigarette users, Achieve aims to address a significant health crisis. With FDA Breakthrough Therapy Designation, cytisinicline is positioned to become the first new prescription treatment for smoking cessation in nearly two decades, offering a promising solution with a favorable safety profile.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.